2,4-pyrimidinediamine compounds and their uses
AssigneeRigel Pharmaceuticals, Inc.
InventorsRajinder Singh, Ankush Argade, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
Life of this patent
Estimating the term…
Abstract
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Claims13
A compound according to Formula (I):
- or a salt thereof, wherein:
- one of R2 and R4 is a phenyl monosubstituted with (C1-C10) alkyl, —ORa optionally substituted with one or more of the same or different Rb groups, —O—C(O)ORa, —O—(CH2)m—C(O)ORa, —C(O)ORa, —O—(CH2)m—NRcRc, —O—C(O)NRcRc, —O—(CH2)m—C(O)NRcRc, —O—C(NH)NRcRc, —O—(CH2)m—C(NH)NRcRc or —NH—(CH2)m—NRcRc;
- the other of R2 and R4 is a phenyl monosubstituted or disubstituted with R8;
- R2 and R4 are different;
- R5 is —NRcRc, CN, or (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups;
- each R8 independently is Ra or Rb;
- each Ra is (C1-C6) alkyl;
- each Rb is —ORa, —OCF3, —NRcRc, halogen, —CF3, —CN, —NO2, —N3, —SO2NRcRc, —C(O)Ra, —C(O)ORc, —C(O)NRcRc, —C(NH)NRcRc, —C(NRa)NRcRc, —C(NOH)Ra, —C(NOH)NRcRc;
- each Rc independently is Ra, hydrogen, or, alternatively, two Rc are taken together with the nitrogen atom to which they are bonded to form a 5- to 8-membered cycloheteroalkyl or heteroaryl;
- and
- each m independently is 1 or 2.
Dependencies are inferred from the claim text.